[Variants of biotechnological drugs in dermatology : Status quo and future].
Varianten biotechnologischer Arzneistoffe in der Dermatologie : Stand und Ausblick.
Antibody therapeutics
Biological products
Biopharmaceutics
Recombinant proteins
Topical application
Journal
Dermatologie (Heidelberg, Germany)
ISSN: 2731-7013
Titre abrégé: Dermatologie (Heidelb)
Pays: Germany
ID NLM: 9918384885206676
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
accepted:
18
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Biotechnological drugs, so-called biopharmaceuticals, have complex structures, have special physicochemical characteristics and are subject to special regulatory laws. In addition to recombinant monoclonal antibodies, proteins and fusion proteins, a large number of biotechnological variations have been developed, of which antibody fragments, nanobodies, peptides, and antibody-drug conjugates in particular have found their way into clinical application. In addition to strategies for the treatment of oncological diseases, chronic inflammatory diseases in particular are being addressed, which are also becoming of great importance in dermatology. The advantages of biopharmaceuticals are increasingly being recognised and developed as part of special strategies for topical application. Due to the rapid development of molecular medicine, new targets for biopharmaceuticals are constantly being identified, and pharmacokinetically favourable biotechnological molecules are being created using refined methods. It can be assumed that this development will lead to even more highly innovative therapeutic and diagnostic options. Biotechnologische Arzneistoffe, sog. Biopharmazeutika, besitzen eine komplexe Struktur, verfügen über physikochemische Besonderheiten und unterliegen speziellen regulatorischen Gesetzmäßigkeiten. Neben rekombinanten monoklonalen Antikörpern, Proteinen und Fusionsproteinen ist eine Vielzahl biotechnologischer Varianten entwickelt worden, von denen insbesondere Antikörperfragmente, Nanobodies, Peptide und Antikörper-Wirkstoff-Konjugate Einzug in die praktische Anwendung gefunden haben. Neben Strategien zur Therapie onkologischer Erkrankungen werden v. a. chronisch-entzündliche Erkrankungen adressiert, die mittlerweile auch in der Dermatologie einen großen Stellenwert besitzen. Die Vorteile von Biopharmazeutika werden zunehmend im Rahmen spezieller Strategien auch für die topische Applikation erkannt und entwickelt. Durch die rasante Entwicklung der molekularen Medizin werden zudem laufend neue Targets für Biopharmazeutika identifiziert und durch verfeinerte Methoden pharmakokinetisch günstige biotechnologische Moleküle kreiert. Es ist davon auszugehen, dass diese Entwicklung noch weitere hochinnovative Therapie- und Diagnostikmöglichkeiten hervorbringen wird.
Autres résumés
Type: Publisher
(ger)
Biotechnologische Arzneistoffe, sog. Biopharmazeutika, besitzen eine komplexe Struktur, verfügen über physikochemische Besonderheiten und unterliegen speziellen regulatorischen Gesetzmäßigkeiten. Neben rekombinanten monoklonalen Antikörpern, Proteinen und Fusionsproteinen ist eine Vielzahl biotechnologischer Varianten entwickelt worden, von denen insbesondere Antikörperfragmente, Nanobodies, Peptide und Antikörper-Wirkstoff-Konjugate Einzug in die praktische Anwendung gefunden haben. Neben Strategien zur Therapie onkologischer Erkrankungen werden v. a. chronisch-entzündliche Erkrankungen adressiert, die mittlerweile auch in der Dermatologie einen großen Stellenwert besitzen. Die Vorteile von Biopharmazeutika werden zunehmend im Rahmen spezieller Strategien auch für die topische Applikation erkannt und entwickelt. Durch die rasante Entwicklung der molekularen Medizin werden zudem laufend neue Targets für Biopharmazeutika identifiziert und durch verfeinerte Methoden pharmakokinetisch günstige biotechnologische Moleküle kreiert. Es ist davon auszugehen, dass diese Entwicklung noch weitere hochinnovative Therapie- und Diagnostikmöglichkeiten hervorbringen wird.
Identifiants
pubmed: 39172184
doi: 10.1007/s00105-024-05403-x
pii: 10.1007/s00105-024-05403-x
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Kinoshita M, Nakajima K, Yamamoto S et al (2021) High-throughput N‑glycan screening method for therapeutic antibodies using a microchip-based DNA analyzer: a promising methodology for monitoring monoclonal antibody N‑glycosylation. Anal Bioanal Chem 413:4727–4738
pubmed: 34080034
doi: 10.1007/s00216-021-03434-0
Kaur H (2021) Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol 41:300–315
pubmed: 33430641
doi: 10.1080/07388551.2020.1869684
Glukhova XA, Prusakova OV, Trizna JA et al (2016) Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique. Curr Pharm Des 22:870–878
pubmed: 26696411
doi: 10.2174/1381612822666151223102845
Alejandra WP, Irene MJP, Antonio FGS et al (2023) Production of monoclonal antibodies for therapeutic purposes: A review. Int Immunopharmacol 120:110376
pubmed: 37244118
doi: 10.1016/j.intimp.2023.110376
Bensalem A, Ternant D (2020) Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clin Pharmacokinet 59:857–874
pubmed: 32170579
doi: 10.1007/s40262-020-00874-2
Yeh TF, Lin C, Sung HC (2023) A review of technological developments in lipid nanoparticle application for mRNA vaccination. Hum Vaccin Immunother 19:2256040
pubmed: 37705354
pmcid: 10503441
doi: 10.1080/21645515.2023.2256040
Jana M, Biswas UK, Patra CS et al (2024) Solid Lipid Nanoparticles: A Review of their Biomedical Applications and. Prep Pharm Nanotechnol
Ho PY, Huang YC (2024) MicroRNA-146a Signature in Psoriasis: A Systematic Review and Meta-Analysis. Mol Diagn Ther
Bantwal PB, Shetty SS, Girisha BS et al (2023) A Study of miRNA 223 Expression and its Correlation with Disease Severity in Chronic Plaque Psoriasis. Indian J Dermatol 68:410–413
pubmed: 37822393
pmcid: 10564193
doi: 10.4103/ijd.ijd_305_23
Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–356
pubmed: 17431406
doi: 10.1038/nrd2241
Guidotti E, Seghieri C, Vinci B et al (2022) Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis. Pharm 15:
Kumar P, Ashawat MS, Kumar A et al (2024) Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy. Curr Pharm Biotechnol
David E, Hawkins K, Shokrian N et al (2024) Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond. Expert Opin Biol Ther
Zhang Y, Jing D, Cheng J et al (2022) The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. Front Immunol 13:923362
pubmed: 35967348
pmcid: 9364267
doi: 10.3389/fimmu.2022.923362
Lebwohl M (2021) Biosimilars in Dermatology. JAMA Dermatol 157:641–642
pubmed: 33825825
doi: 10.1001/jamadermatol.2021.0219
Thomas SE, Barenbrug L, Hannink G et al (2024) Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. Drugs 84:565–578
pubmed: 38630365
pmcid: 11190018
doi: 10.1007/s40265-024-02028-1
Shi J, Xu J, Chen Y (2020) A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis. Dermatol Ther 33:e13802
pubmed: 32521069
doi: 10.1111/dth.13802
Soul J, Carlsson E, Hofmann SR et al (2024) Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis. Clin Immunol 265:110283
pubmed: 38880200
doi: 10.1016/j.clim.2024.110283
He S, Liu L, Long X et al (2024) Single-cell analysis and machine learning identify psoriasis-associated CD8(+) T cells serve as biomarker for psoriasis. Front Genet 15:1387875
pubmed: 38915827
pmcid: 11194350
doi: 10.3389/fgene.2024.1387875
Martin A, Thatiparthi A, Liu J et al (2022) Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review. J Clin Aesthet Dermatol 15:S19–S31
pubmed: 35784449
pmcid: 9197149
Gustafson CJ, Watkins C, Hix E et al (2013) Combination therapy in psoriasis: an evidence-based review. Am J Clin Dermatol 14:9–25
pubmed: 23329077
doi: 10.1007/s40257-012-0003-7
Diotallevi F, Paolinelli M, Radi G et al (2022) Latest combination therapies in psoriasis: Narrative review of the literature. Dermatol Ther 35:e15759
pubmed: 35959523
pmcid: 9786636
doi: 10.1111/dth.15759
Yee D, Kingston P, Lee K et al (2023) Shared decision-making and satisfaction with care in patients with psoriasis: A population-based study in the United States. J Am Acad Dermatol 89:920–926
pubmed: 37011814
doi: 10.1016/j.jaad.2023.03.039
Quiles-Tsimaratos N, Paul C, De La Brassinne M et al (2023) Decision-making factors for the long-term topical treatment of mild-to-moderate plaque psoriasis: TEPPSO, a case-vignette study on clinical practice. Ann Dermatol Venereol 150:28–34
pubmed: 35787804
doi: 10.1016/j.annder.2022.05.003
Nicolescu AC, Ionescu MA, Constantin MM et al (2022) Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and. Eff Life 12:
Kikuchi R, Kingston P, Hao A et al (2024) Shared decision-making in psoriasis care: Evaluation of how patients’ perception of clinicians’ delivery of care changes by age and sex. PLoS ONE 19:e303058
pubmed: 38728289
pmcid: 11086864
doi: 10.1371/journal.pone.0303058
Proctor JR, Wong H (2024) Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature. Clin Transl Sci 17:e13676
pubmed: 37905360
doi: 10.1111/cts.13676
Lin YC, Chen BM, Tran TTM et al (2023) Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. J Control Release 354:354–367
pubmed: 36641121
doi: 10.1016/j.jconrel.2023.01.021
Alas M, Saghaeidehkordi A, Kaur K (2021) Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem 64:216–232
pubmed: 33382619
doi: 10.1021/acs.jmedchem.0c01530
Li Y, Su J, Tan S et al (2024) Research progress on novel antibody drug conjugates in cancer therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 49:296–304
pubmed: 38755726
Su Z, Xiao D, Xie F et al (2021) Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B 11:3889–3907
pubmed: 35024314
pmcid: 8727783
doi: 10.1016/j.apsb.2021.03.042
Aslam S, Zulfiqar F, Hameed W et al (2024) Fusion proteins development strategies and their role as cancer therapeutic agents. Biotechnol Appl Biochem 71:81–95
pubmed: 37822167
doi: 10.1002/bab.2523
Duivelshof BL, Murisier A, Camperi J et al (2021) Therapeutic Fc-fusion proteins: Current analytical strategies. J Sep Sci 44:35–62
pubmed: 32914936
doi: 10.1002/jssc.202000765
Marsh MC, Owen SC (2023) Therapeutic Fusion Proteins. AAPS J 26:3
pubmed: 38036919
doi: 10.1208/s12248-023-00873-8
Sanchez Carazo JL, Mahiques SL, Martinez OV (2006) Safety of etanercept in psoriasis: a critical review. Drug Saf 29:675–685
pubmed: 16872241
doi: 10.2165/00002018-200629080-00004
Goldsmith DR, Etanercept WAJ (2005) a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 6:121–136
pubmed: 15799687
doi: 10.2165/00128071-200506020-00010
Lee A, Certolizumab Pegol SLJ (2020) A Review in Moderate to Severe Plaque Psoriasis. BioDrugs 34:235–244
pubmed: 32207094
doi: 10.1007/s40259-020-00416-z
Clowse M, Fischer-Betz R, Nelson-Piercy C et al (2022) Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol. Ther Adv Musculoskelet Dis 14: (1759720X221087650)
Labrijn AF, Janmaat ML, Reichert JM et al (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18:585–608
pubmed: 31175342
doi: 10.1038/s41573-019-0028-1
Beishenaliev A, Loke YL, Goh SJ et al (2023) Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. J Control Release 359:268–286
pubmed: 37244297
doi: 10.1016/j.jconrel.2023.05.032
Reich K, Cullen E, Weinberg M (2022) Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? Br J Dermatol 187:591–593
pubmed: 35442535
doi: 10.1111/bjd.21617
Papp KA, Weinberg MA, Morris A et al (2021) IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet 397:1564–1575
pubmed: 33894834
doi: 10.1016/S0140-6736(21)00440-2
Ståhl S, Gräslund T, Eriksson Karlström A et al (2017) Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol 35:691–712
pubmed: 28514998
doi: 10.1016/j.tibtech.2017.04.007
Klint S, Feldwisch J, Gudmundsdotter L et al (2023) Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. mAbs 15:2209920
pubmed: 37184136
pmcid: 10187109
doi: 10.1080/19420862.2023.2209920
Gerdes S, Staubach P, Dirschka T et al (2023) Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol 189:381–391
pubmed: 37697683
doi: 10.1093/bjd/ljad186
Behrens F, Taylor PC, Wetzel D et al (2022) Izokibep (Aby-035) in patients with active psoriatic arthritis—16-week results from a phase 2 study. Ann Rheum Dis 81:170–171
doi: 10.1136/annrheumdis-2022-eular.536
Papp K (2023in) Izokibep, a novel IL-17A inhibitor, demonstrates HiSCR100 response in moderate-to-severe Hidradenitis suppurativa: Open-label Part A results of a phase 2b/3 study. Late breaking news lecture. AAD Annu Meet (in New Orleans)
Stoltz C New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year—JNJ-2113 long-term extension. https://www.jnj.com/media-center/press-releases/new-data-shows-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year . Zugegriffen: 26. Juni 2024
Liu K, Li M, Li Y et al (2024) A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Mol Cancer 23:62
pubmed: 38519953
pmcid: 10960395
doi: 10.1186/s12943-024-01963-7
Chavda VP, Balar PC, Teli D et al (2023) Antibody-Biopolymer Conjugates in Oncology: A Review. Molecules 28:
Darbandi A, Abdi M, Dashtbin S et al (2024) Antibody-Antibiotic Conjugates: A Comprehensive Review on Their Therapeutic Potentials Against BacterialInfections. J Clin Lab Anal e25071:
Kesireddy M, Kothapalli SR, Gundepalli SG et al (2024) A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. Pharmaceut Med 38:39–54
pubmed: 38019416
Bae DH, Bae H, Yu HS et al (2024) Peptide-Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis-Like Inflammation. Adv Healthc Mater 13:e2303480
pubmed: 38421096
doi: 10.1002/adhm.202303480
Santora LC, Hobson AD, Wang L et al (2024) Impact of drug-linker on method selection for analytical characterization and purification of antibody-drug conjugates. Anal Methods 16:3492–3503
pubmed: 38770747
doi: 10.1039/D4AY00725E
Goodman R, Johnson DB (2022) Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. Curr Treat Options Oncol 23:1428–1442
pubmed: 36125618
doi: 10.1007/s11864-022-01018-3
Walsh S, Kokai-Kun J, Shah A, Mond J (2004) Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semisolid or polymeric carriers. Pharm Res 21:1770–1775
pubmed: 15553221
doi: 10.1023/B:PHAM.0000045227.16829.37
Wang Y, Cheetham AG, Angacian G, Su H, Xie L, Cui H (2017) Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv Drug Deliv Rev: 112–126